NEVVI Medicare utilization intelligence
or

← back

Provider profile

RATHI, SHIKHA MBBS, MD

Rheumatology · NPI 1093083552 · PHILADELPHIA, PA

1
Groups
19
Codes · 2024
92,617
Disclosed services

RATHI, SHIKHA is a Rheumatology in PHILADELPHIA, PA, a member of 1 medical group, who billed 19 distinct codes to Medicare Part B in 2024.

Groups: ARTHRITIS GROUP PC (LANGHORNE, PA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

92,617
disclosed services
19
codes billed to Medicare Part B
Prior year · CY2023 36,661 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J3262 Injection, tocilizumab, 1 mg
J1602 Injection, golimumab, 1 mg, for intravenous use
J3111 Injection, romosozumab-aqqg, 1 mg
J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
J1745 Injection, infliximab, excludes biosimilar, 10 mg
J0897 Injection, denosumab, 1 mg
J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
J1010 Injection, methylprednisolone acetate, 1 mg
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96413 Administration of chemotherapy into vein, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96372 Injection of drug or substance under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
J3489 Injection, zoledronic acid, 1 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
20610 Aspiration and/or injection of fluid from large joint
96375 Injection of additional new drug or substance into vein
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.